Asia Pacific: Korea Healthcare Outlook 2010

P3B5-54

April 2010

Asia Pacific Healthcare Outlook

Focus : South Korea Analysis of Best Opportunities

2P3B5-54

Disclaimer

• Frost & Sullivan takes no responsibility for the incorrect information supplied to us by manufacturers or users.

• Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation.

• Frost & Sullivan Research Services are limited publications containing valuable market information provided to a select group of customers in response to orders. Our customers acknowledge, when ordering, that Frost & Sullivan Research Services are for customers’ internal use and not for general publication or disclosure to third parties.

• No part of this Research Service may be given, lent, resold, or disclosed to non-customers without written permission.

• Furthermore, no part may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the permission of the publisher.

• For information regarding permission, write to:

Frost & Sullivan GIC Malaysia Sdn. Bhd.

Suite E-08-15, Block E

Plaza Mont’ Kiara

2 Jalan Kiara, Mont’ Kiara

50480 Kuala Lumpur.

© 2010 Frost & Sullivan. All rights reserved. This document contains highly confidential information and is the sole property of Frost & Sullivan. No part of it may be circulated, quoted, copied or otherwise reproduced without the written approval of Frost & Sullivan.

3P3B5-54

Certification

• We hereby certify that the views expressed in this research service accurately reflect our views based on primary

and secondary research with industry participants, industry experts, end users, regulatory organizations, financial

and investment community, and other related sources.

• In addition to the above, our robust in-house forecast & benchmarking models along with the Frost & Sullivan

Decision Support Databases have been instrumental in the completion and publishing of this research service.

• We also certify that no part of our analyst compensation was, is or will be, directly or indirectly, related to the

specific recommendations or views expressed in this research service.

4P3B5-54

TABLE OF CONTENT

1. Overview of Healthcare Market : Key Takeaways

• Setting the Scene: Outlook for Healthcare Industry from 2010-12

• Global vs. APAC: The New Frontier

2. In-depth Sectoral Analysis, APAC and South Korea

• APAC Pharmaceuticals & Biotechnology Market

• South Korea Pharmaceuticals & Biotechnology Market

• Top Growth Opportunities : S. Korea Pharmaceuticals and Biotech Market

• APAC Medical Equipment Market

• South Korea Medical Equipment Market

• Top Growth Opportunities : S Korea Medical Equipment Market

• APAC Lifesciences and Health IT Market

• South Korea Health IT Market

• Top Growth Opportunities : South Korea Health IT Market

3. Summary : Best Opportunity Analysis, APAC and South Korea

• Where to place your bets in APAC: 2010- 2012

• Where to place your bets in S. Korea : 2010- 2012

5P3B5-54

TABLE OF CONTENT

4. Decision Support Database

• Total Health Expenditure

• Private Health Expenditure

• Government Health Expenditure

• Percent Healthcare Expenditure in GDP

• Population Aged Above 65

5. About Frost & Sullivan

6

Overview of Healthcare Market : Key Takeaways

7P3B5-54

Setting the Scene Outlook for Healthcare Industry from 2010-12

Global Healthcare Market : 2009

• US and Europe were impacted in a major way by global crisis

• Asia also slowed down but not as much as the West

• Valuations were low and M&A was high, many smaller Biotech companies struggled

• Major organizational restructuring occurred, along with portfolios being reassessed

Global Healthcare Market : 2010-12

• Recovery of the markets to a large extent with strong growth in Asia

• Start of major patent expiries

• M&A activity down in the West but could be important in Asia, restructuring will continue

• Asia becoming increasingly important as a market and outsourcing hub

• 5Ps to drive market: Preventive, Preemptive, Personalized, Predictive, Personal Responsibility

8P3B5-54

Global vs. APAC: The New FrontierBy 2012 APAC expected to be close to 27% of global market

23.9%23.9%

27.2%27.2%

23.2%23.2%

26.4%26.4%

CAGR12.2%CAGR12.2%

CAGR6.47%CAGR6.47%

Global & APAC Healthcare Revenues US$ Bn, 2009-2012

• By 2015 APAC could represent ~40% of global market!

Rest of the World

APAC

Note: All figures are rounded; the base year is 2009. Source: Frost and SullivanNote: All figures are rounded; the base year is 2009. Source: Frost and Sullivan

9P3B5-54

Asia is however transitioningMoving toward a Multi–Polar World Order

Asia Pacific Market : 2009

• Slowing down of GDP in mature markets – Japan and Australia took a big hit

• Global consolidation left a difficult mess for integration on a local level – job losses and portfolio realignment

• Price cutting and playing the margins game

• The bubble burst for Medical Tourism

• Asia started to set up infrastructure for offshoring and outsourcing for US/EU companies

Asia Pacific Market : 2012

• A shift in the center of the world economically and strategically to Asia

• Asia to move from export led development to consumption led growth

• APAC the fastest growing pharma market and API production hub

• Increased government attention to primary and community based healthcare.

• Increased use of mobile technology in healthcare service delivery

• 2010 : Malaysia Innovation and Creativity year

10

In-depth Sectoral Analysis, APAC and South Korea

11P3B5-54

APAC Pharmaceuticals & Biotechnology MarketEarlier diagnosis improves disease management and length of therapy


Market Drivers

Market Restraints

Long term use of multiple and specialized drugs for the ageing population

Government support for generics and biosimilars

Enhanced diagnosis and management in oncology, cardiovascular, pain etc

Unresolved political and regulations issues Quality concern of generics & counterfeits

Government tenders favour local manufacturers

24.6% 28.5%

CAGR6.6 %

CAGR6.6 %

CAGR12.9 %CAGR12.9 %

Pharma & Biotech Revenues, US$ Bn, 2009-2012

APAC Share

750825 866 909

12P3B5-54

South Korea Pharmaceuticals & Biotechnology MarketStrong commitment to biotechnology

Pharma & Biotech Revenues, US$ Bn, 2009-2012 Market Drivers

Market Restraints

Intensified competition from MNC ethical products post 2007 FTA will restrain growth of domestic players•Lowered profits for branded and generic drugs owing to shift to Positive List System

• Growing demand for lifestyle diseases drugs e.g. hypertension ,diabetes, oncology• Increased drug imports owing to changes in reimbursement and dispensing policy• Highly competitive generics market and government commitment to develop super generics

13P3B5-54

S Korea Cardiovascular Diseases market 2010 :~ US$ 2.27 bn; estimated size in 2012 : ~US$ 2.9 bn; CAGR ~ 13%

S Korea Diabetes market 2010 ~ US$ 495 mn; estimated size in 2012 ~ US$ 609mn; CAGR ~ 10.9%

Prevalence of diabetes : 2010 : ~3.5 mn. Potential for diagnosis and treatment as nearly 45% of cases are undiagnosed

0

0

Source: Frost & Sullivan. http://www.pfizer.com/

Bio-pharmaceuticals

Bio-pharmaceuticals

Cardiovascular and metabolic

diseases

Cardiovascular and metabolic

diseases

Oncology Oncology

S Korea Oncology market in 2010 : ~ US$ 840 mn; CAGR ~ 17-20%

Growth from early diagnosis of cancers and targeted therapy in top 3 types of cancer : lung cancer, gastric cancer and liver cancer

Potential for generic oncology drugs as this currently comprise 20% share in a market dominated by MNCs

Top Growth Opportunities : S. Korea Pharmaceuticals and Biotech Market

2009 : biopharmaceuticals identified as a growth engine for the Korean economy.

Planned government support for generics and super generics : ~US$ 1 bn from 2007 -2017

Local domestic players have already initiated production of next generation protein therapeutics (bio – betters) : targeted at global markets

S Korea generics market 2010 : ~ US$ 4 bn; CAGR ~ 12.1%

14P3B5-54

APAC Medical Equipment MarketTransition to a mindset of monitoring

Medical Equipment Revenues, US$ Bn, 2009-2012

59.4

65.472.0

79.4


Market Drivers

• Safety, accuracy, efficiency, cost

• Automation and integration with information systems

•Emphasis on early detection and monitoring

•Silver industry requirements

Market Restraints

• Regulatory and reimbursement hurdles

• Inadequate distribution networks

• Inadequate training on and compliance to new technology

15P3B5-54

South Korea Medical Equipment MarketFocus on high end and innovative technology

Medical Equipment Revenues, US$ Bn, 2009-2012

Market Drivers

Market Restraints

• Demand for advanced and innovative medical equipment

• Ageing population

•Increased prevalence of chronic and lifestyle diseases

• High financing deficit of NHIC

• Strong reliance on imports in relation to domestic manufacture

• High currency fluctuations


16P3B5-54

Molecular diagnostics and laboratory automation products will prosper as Korean hospitals strive to provide the world's best and aim to achieve the highest cure rates for various lifestyle diseases like cancer (especially stomach- and liver) and complex surgeries like liver transplantations.

0

0

Top Growth Opportunities : S Korea Medical EquipmentMarket

Minimal Invasive &

Cosmetic Surgery

Minimal Invasive &

Cosmetic Surgery

Clinical Diagnostics

Clinical Diagnostics

Medical Imaging Medical Imaging

Growth in traditional products like Linear Accelerators, High end CT and MR and SPECT spur as consumers demand personalised treatment and services

Next Generation Broadband services will lead to creation of u-health products wherein consumers can be diagnosed in real time mode

Source: Frost & Sullivan.

Cardiovascular, endoscopy, laparoscopy, ophthalmic and dental devices. This segment will be driven by increased prevalence of chronic and age related diseases .

Other remarkable specialties include plastic surgery, oriental medicine, dental care

17P3B5-54


*Healthcare IT includes: Software, Hardware, IT services and Lifesciences IT

APAC Lifesciences and Health IT Market*Interoperability challenges hinder adoption

14.5%14.5%

15.7%15.7%

Market Drivers

Market Restraints

Operational efficiency Strong and sustained demand for healthcare services

Consumer demand for quality and access to information

Interoperability

Integration

Lack of skilled resources

Lifesciences & Healthcare IT, US$ Bn, 2009-2012

CAGR7%

CAGR7%

CAGR11.3%CAGR11.3%

APAC Share

50.654.6

58.4 62.5

18P3B5-54

South Korea Health IT MarketEMR/EHR fast becoming the norm

263 280.5 299.5 320

0

50

100

150

200

250

300

350

2009 2010 2011 2012

CAGR 6..8%

Health IT Revenues, US$ Mn, 2009-2012

Market Drivers

Market Restraints

*Health IT includes: Software, Hardware, IT services, Networking

• Government subsidies to provider s who use state – of – the –art technology

• Regulations requiring use of EMR/EHR and telemedicine

•Thrust on medical tourism

Insufficient regulation in the free-standing delivery network which includes diagnostic centers and group practices.

Security and Privacy issues stall buy in from national entities such as Korea Medical Association and Citizen’s group


19P3B5-54

0

0

0Electronic Health

RecordElectronic Health

Record

Business Intelligence

Solution

Business Intelligence

Solution

Healthcare Interoperability Standards and

Platform

Healthcare Interoperability Standards and

Platform

Top Growth Opportunities : S. Korea Health IT Market

Korea market 2010 (Business Intelligence) : ~US$ 48 mn; CAGR ~8.5%

Growing demand for patient centered healthcare services and systemized healthcare organization management through the implementation of advanced healthcare systems

Korea market 2010 (Healthcare Interoperability Platform (HIP) and Master Patient Index, Health Information Exchange and related Standards and Adaptors) : ~US$ 28 mn; CAGR ~7.5%

Various standards for systematic, efficient record system, sharing, management of health information system have been appearing, as there is a growing demand for necessity to adopt health information system interoperability.


Korea market 2010 (EHR) : ~US$ 63 mn; CAGR ~ 10%

The Centre for iEHR (CiEHR ) a research and development institute,established in December, 2005 in support of Korean Ministry of Health & Welfare to develop core technologies necessary to implement lifetime EHR

20

Summary : Best Opportunity Analysis APAC and South Korea

21P3B5-54

Where to place your bets in APAC: 2010- 2012

Time

Gro

wth Molecular

Diagnostics

Silver IndustryEquipment

POCT

Vaccines/Biologics

Endoscopy

EMR/EHR

WellnessProducts

Oncology

Value basedImaging

INNOVATIONTRIGGER

SUPERGROWTH

NORMALISATION LEADERSHIP

IndiaChina

S.Korea

SingaporeMalaysia

Vietnam

HealthcareServices


22P3B5-54

Where to place your bets in South Korea : 2010- 2012

Time

Gro

wth Wellness

Products

Next Gen Broadband

Endoscopy EMR/EHR

Molecular Diagnostics Oncology

INNOVATIONTRIGGER

SUPERGROWTH

NORMALISATION LEADERSHIP

HealthcareServices


Generics

Silver Industry

CardiovascularOrthopedics

POCT, Self Monitoring Devices

23

Decision Support Database

• Total Health Expenditure

• Private Health Expenditure

• Government Health Expenditure

• Percent Healthcare Expenditure in GDP

• Population Aged Above 65

24P3B5-54

Decision Support Databases

Decision Support DatabaseTable Total Healthcare Expenditure (Bn USD)

Region / Country 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012CAGR %

(2005 - 2012)North America

Canada 73.0 87.8 101.2 116.9 129.5 138.3 147.0 155.2 163.0 169.8 175.9 6.00United States 1,559.0 1,678.9 1,804.7 1,936.6 2,077.5 2,232.9 2,399.2 2,573.3 2,753.9 2,944.2 3,146.3 7.18

TOTAL 1,632.0 1,766.6 1,905.9 2,053.5 2,207.0 2,371.2 2,546.3 2,728.6 2,916.8 3,114.0 3,322.1 7.11

Latin America

Argentina 11.5 14.7 17.3 20.9 23.3 25.7 27.8 29.9 31.8 33.7 35.5 7.85Brazil 40.7 45.8 55.6 74.0 78.8 83.8 90.0 97.0 104.9 113.7 123.6 7.60Chile 3.8 4.4 5.8 7.0 8.0 9.0 9.9 10.8 11.8 12.8 13.8 10.17Mexico 59.6 58.5 62.2 72.3 78.8 84.7 91.0 97.5 104.0 110.4 116.7 7.08Peru 2.4 2.7 3.1 3.6 3.9 4.2 4.5 4.9 5.2 5.6 5.9 7.46Venezuela 4.7 4.7 6.2 7.2 8.2 9.3 10.5 11.8 13.4 15.3 17.7 13.82

TOTAL 122.7 130.8 150.2 185.0 200.9 216.7 233.8 251.8 271.1 291.5 313.2 7.81

Asia - Pacific

Australia 39.4 51.0 62.4 69.9 74.7 79.9 85.1 90.4 95.9 101.4 107.1 6.29China 71.9 84.3 98.7 116.0 134.3 152.9 172.5 193.7 217.0 242.5 270.7 12.87Hong Kong 9.4 9.5 10.0 10.9 11.9 13.0 14.1 15.5 16.9 18.5 20.3 9.25India 27.5 36.1 41.9 48.5 54.0 59.8 66.1 72.8 80.0 87.5 95.5 10.16Indonesia 6.4 8.0 8.8 9.3 10.6 12.0 13.5 15.3 17.3 19.6 22.2 13.15Japan 315.4 339.5 374.9 379.7 394.0 406.6 414.7 424.9 437.0 451.7 467.5 3.02Malaysia 3.6 4.0 4.6 5.2 5.9 6.7 7.6 8.6 9.6 10.8 11.9 12.66New Zealand 5.1 6.7 8.5 9.4 10.4 11.4 12.3 13.1 13.8 14.4 14.9 6.77Philippines 2.3 2.3 2.5 2.8 3.2 3.6 4.0 4.4 4.9 5.5 6.0 11.45Singapore 3.7 4.0 4.3 4.6 5.0 5.3 5.7 6.2 6.6 7.1 7.6 7.46South Korea 25.3 30.1 33.9 39.3 43.3 47.7 52.2 56.7 61.2 66.0 70.9 8.81Taiwan 16.9 17.8 19.2 21.0 22.8 24.7 26.5 28.2 30.0 31.8 33.6 6.92Thailand 7.8 8.5 9.6 10.7 11.9 13.3 14.8 16.6 18.7 21.1 23.8 12.18

TOTAL 534.6 601.6 679.2 727.3 781.9 836.8 889.1 946.3 1,008.8 1,077.7 1,152.0 6.79

25P3B5-54

Decision Support Databases (Contd…)



(2005 - 2012)Western Europe

Austria 15.3 19.2 22.1 23.1 24.0 24.8 25.7 26.5 27.2 27.9 28.5 3.04Belgium 22.6 29.3 34.0 35.8 37.4 38.9 40.3 41.6 42.9 44.1 45.3 3.40Denmark 15.2 19.2 22.2 23.4 24.4 25.4 26.4 27.4 28.3 29.3 30.3 3.78Finland 9.5 11.8 13.6 14.4 15.1 16.0 16.9 17.7 18.5 19.3 20.1 4.90France 139.0 176.8 205.6 217.9 228.6 239.0 249.3 259.1 268.4 277.8 286.6 3.99Germany 211.1 258.9 294.6 305.9 314.9 323.7 332.6 341.2 349.3 358.1 366.6 2.62Greece 13.0 17.2 19.6 22.3 23.9 25.4 27.0 28.6 30.2 31.8 33.4 5.99Iceland 0.8 1.1 1.3 1.6 1.8 2.0 2.1 2.3 2.4 2.6 2.7 7.80Ireland 9.7 12.8 15.4 16.3 17.9 19.3 20.8 22.3 23.8 25.3 26.8 7.43Italy 99.6 122.3 139.7 143.4 149.1 154.0 159.0 163.8 168.1 172.0 175.4 2.92Luxembourg 1.5 1.9 2.3 2.5 2.7 2.8 2.9 3.0 3.2 3.3 3.4 4.14Netherlands 39.0 50.4 58.1 60.6 63.8 66.2 68.7 71.1 73.3 75.5 77.6 3.59Norway 18.3 22.7 26.1 30.4 32.5 34.7 36.9 39.3 41.4 43.4 45.5 5.94Portugal 11.3 14.3 16.5 17.3 18.2 19.1 20.0 20.9 21.9 22.8 23.8 4.60Spain 49.7 65.0 77.1 88.4 94.4 100.2 106.1 112.1 117.6 123.2 128.1 5.45Sweden 22.2 28.4 33.5 34.1 35.6 37.1 39.2 41.4 43.9 46.6 49.7 5.53Switzerland 29.7 37.0 41.5 43.1 45.7 48.4 51.1 53.8 56.5 59.3 62.2 5.39United Kingdom 121.0 141.5 170.0 180.7 191.9 203.3 214.8 227.0 238.7 250.4 262.6 5.49

TOTAL 828.6 1,029.6 1,193.2 1,261.1 1,321.7 1,380.3 1,439.8 1,499.0 1,555.5 1,612.8 1,668.5 4.08

Eastern Europe

Czech Republic 5.0 6.8 7.5 9.0 9.9 10.8 11.7 12.7 13.6 14.5 15.5 8.03Hungary 4.9 6.9 8.6 9.6 10.8 11.8 12.9 13.9 14.9 15.9 16.8 8.23Poland 12.5 13.6 15.2 17.9 19.7 21.2 22.9 24.7 26.5 28.2 29.8 7.59Russia 21.3 26.2 32.6 38.2 43.7 48.8 53.9 58.7 63.4 67.9 72.2 9.51Turkey 11.6 15.8 19.7 26.0 28.6 31.5 34.0 36.4 39.0 41.2 43.3 7.55

TOTAL 55.4 69.3 83.6 100.8 112.6 124.1 135.3 146.4 157.3 167.7 177.6 8.43

26P3B5-54




(2005 - 2012)Middle East & Africa

Egypt 4.0 3.5 3.7 4.4 5.5 6.5 7.5 8.5 9.7 11.0 12.4 16.03Israel 9.0 9.7 10.4 11.0 11.8 12.5 13.2 14.2 15.3 16.5 17.8 7.05Saudi Arabia 7.9 8.8 9.6 10.4 11.2 11.8 12.4 13.0 13.6 14.2 14.8 5.13South Africa 9.1 13.6 20.0 19.6 20.5 21.6 22.7 23.9 25.2 26.7 28.4 5.50

TOTAL 30.0 35.5 43.6 45.4 49.0 52.4 55.8 59.6 63.7 68.3 73.4 7.11

WORLD TOTAL 3,203.3 3,633.5 4,055.6 4,373.0 4,673.2 4,981.4 5,300.0 5,631.6 5,973.3 6,331.9 6,706.8 6.30

Note: All figures are rounded; the base year is 2005. Source: Frost & SullivanDefinition

Note1. Figures for 2005 are Frost & Sullivan estimates

The above figures indicate health care expenditure

Source: Frost & SullivanSource: Frost & Sullivan

27P3B5-54


Decision Support DatabaseTable Private Healthcare Expenditure (Bn USD)



Canada 22.2 26.2 30.5 35.6 39.7 42.6 45.5 48.3 50.8 53.1 55.2 6.48United States 841.0 913.2 980.5 1,045.3 1,078.0 1,155.7 1,240.9 1,330.0 1,421.0 1,517.4 1,614.5 6.41

TOTAL 863.2 939.4 1,011.0 1,080.8 1,117.7 1,198.3 1,286.4 1,378.2 1,471.9 1,570.5 1,669.7 6.41

Latin America


TOTAL 66.4 71.0 81.4 100.5 109.8 118.6 128.0 137.9 148.4 159.5 171.3 7.92

Asia - Pacific


TOTAL 177.0 204.7 235.1 264.9 293.2 320.2 345.1 372.0 401.5 435.7 472.6 8.62

28P3B5-54






TOTAL 208.8 262.0 302.3 319.3 331.4 345.0 358.5 371.7 382.7 394.2 404.7 3.45

Eastern Europe


TOTAL 18.8 23.5 28.7 34.8 39.0 43.2 47.4 51.4 55.4 59.2 62.9 8.84

29P3B5-54






TOTAL 14.0 16.7 22.0 23.1 25.2 27.3 29.3 31.6 34.1 36.9 40.0 8.17

WORLD TOTAL 1,348.2 1,517.3 1,680.4 1,823.3 1,916.3 2,052.5 2,194.7 2,342.7 2,493.8 2,655.8 2,821.2 6.43



Figures in the table represents private health expenditure


30P3B5-54


Decision Support DatabaseTable Government Healthcare Expenditure (Bn USD)



Canada 50.8 61.6 70.7 81.4 89.8 95.7 101.5 107.0 112.1 116.7 120.7 5.79United States 718.0 765.7 824.2 891.3 999.5 1,077.2 1,158.4 1,243.4 1,332.9 1,426.8 1,531.8 8.04

TOTAL 768.8 827.3 895.0 972.7 1,089.3 1,172.9 1,259.9 1,350.3 1,445.0 1,543.5 1,652.5 7.87

Latin America


TOTAL 56.3 59.8 68.8 84.5 91.1 98.1 105.8 113.9 122.7 132.0 141.9 7.69

Asia - Pacific


TOTAL 357.5 396.9 444.1 462.4 488.8 516.7 543.9 574.3 607.3 642.0 679.4 5.65

31P3B5-54






TOTAL 619.8 767.6 890.9 941.8 990.3 1,035.3 1,081.3 1,127.3 1,172.8 1,218.6 1,263.7 4.29

Eastern Europe


TOTAL 36.6 45.9 54.9 66.0 73.7 80.9 88.0 95.1 102.0 108.5 114.7 8.21

32P3B5-54






TOTAL 16.0 18.8 21.6 22.3 23.7 25.1 26.5 28.1 29.7 31.5 33.3 5.93

WORLD TOTAL 1,855.1 2,116.2 2,375.2 2,549.6 2,756.9 2,929.0 3,105.3 3,288.9 3,479.5 3,676.2 3,885.5 6.20



The above figures indicate health care expenditure by government


33P3B5-54

Decision Support DatabaseTable Percent Healthcare Expenditure in GDP

Region / Country 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012North America

Canada 9.9 10.1 10.2 10.3 10.4 10.7 11.0 11.2 11.4 11.5 11.6United States 14.9 15.3 15.4 15.2 15.4 15.6 15.9 16.3 16.6 17.0 17.4

TOTAL 14.6 14.9 15.0 14.8 15.0 15.2 15.5 15.8 16.2 16.5 16.9

Latin America

Argentina 11.3 11.3 11.3 11.4 11.5 11.7 11.8 11.9 12.0 12.2 12.4Brazil 9.1 9.1 9.2 9.3 9.3 9.3 9.3 9.3 9.4 9.5 9.6Chile 5.8 6.0 6.1 6.4 6.4 6.5 6.5 6.5 6.6 6.7 6.7Mexico 9.2 9.4 9.4 9.4 9.6 9.8 9.9 10.1 10.3 10.5 10.7Peru 4.4 4.5 4.5 4.6 4.7 4.8 4.9 5.0 5.2 5.3 5.5Venezuela 4.9 5.5 5.5 5.6 5.7 5.7 5.8 5.8 5.9 5.9 5.9

TOTAL 8.7 8.8 8.9 9.0 9.0 9.1 9.2 9.2 9.3 9.4 9.5

Asia - Pacific

Australia 9.6 9.7 9.9 10.5 10.7 10.9 11.0 11.1 11.2 11.4 11.7China 5.7 6.0 6.0 6.1 6.4 6.6 6.8 7.0 7.1 7.3 7.5Hong Kong 5.8 6.1 6.2 6.2 6.3 6.6 6.8 6.9 7.1 7.3 7.5India 6.1 6.1 6.4 6.4 6.5 6.6 6.7 6.7 6.8 6.9 6.9Indonesia 3.7 3.4 3.4 3.5 3.5 3.5 3.6 3.7 3.8 3.9 4.0Japan 6.8 6.9 7.0 7.0 7.4 7.9 7.7 7.7 7.8 7.8 7.8Malaysia 3.8 3.9 3.9 4.0 4.1 4.3 4.4 4.6 4.7 4.8 5.0New Zealand 8.7 8.6 8.7 9.0 9.2 9.3 9.5 9.7 9.8 9.9 9.9Philippines 2.9 2.9 2.9 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.1Singapore 3.8 3.9 3.9 3.9 3.9 4.0 4.0 4.0 4.0 4.1 4.2South Korea 4.9 4.9 5.0 5.0 5.1 5.1 5.2 5.2 5.2 5.3 5.3Taiwan 6.0 6.0 6.1 6.1 6.1 6.1 6.2 6.2 6.3 6.3 6.3Thailand 5.8 5.9 5.9 6.1 6.2 6.3 6.4 6.6 6.8 7.1 7.5

TOTAL 6.4 6.5 6.6 6.6 6.8 7.1 7.0 7.1 7.2 7.2 7.3


34P3B5-54



Region / Country 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

Western Europe

Austria 7.5 7.5 7.6 7.6 7.6 7.6 7.6 7.6 7.6 7.7 7.7Belgium 9.1 9.6 9.6 9.7 9.8 9.9 9.9 10.0 10.1 10.2 10.3Denmark 8.8 9.1 9.2 9.1 9.2 9.3 9.4 9.5 9.5 9.5 9.5Finland 7.2 7.3 7.3 7.5 7.6 7.6 7.7 7.7 7.7 7.8 7.8France 9.7 9.8 10.0 10.3 10.5 10.7 10.8 10.9 11.0 11.1 11.3Germany 10.6 10.6 10.7 10.9 11.1 11.2 11.3 11.4 11.5 11.7 11.9Greece 9.8 9.9 9.9 10.0 10.1 10.2 10.2 10.3 10.2 10.3 10.3Iceland 9.9 10.5 10.6 10.6 10.9 11.1 11.3 11.5 11.7 11.9 12.0Ireland 8.0 8.4 8.5 8.6 8.8 9.0 9.2 9.3 9.5 9.7 9.9Italy 8.4 8.3 8.3 8.4 8.4 8.4 8.4 8.5 8.5 8.5 8.5Luxembourg 6.9 6.9 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.7Netherlands 9.3 9.8 9.8 10.6 10.9 11.0 11.1 11.2 11.3 11.4 11.6Norway 9.6 10.3 10.4 10.4 10.6 10.8 11.0 11.2 11.4 11.6 11.8Portugal 9.3 9.7 9.9 10.1 10.2 10.3 10.5 10.6 10.7 10.9 11.0Spain 7.6 7.7 7.8 7.9 7.9 8.0 8.1 8.2 8.2 8.3 8.4Sweden 9.2 9.4 9.6 9.7 9.9 10.0 10.1 10.2 10.3 10.4 10.6Switzerland 11.1 11.5 11.5 11.7 11.8 11.9 12.0 12.1 12.3 12.4 12.6United Kingdom 7.7 7.8 8.0 8.2 8.4 8.6 8.8 9.0 9.2 9.3 9.5

TOTAL 9.0 9.1 9.2 9.3 9.5 9.6 9.7 9.8 9.9 10.0 10.1

Eastern Europe

Czech Republic 7.2 7.5 7.5 7.6 7.6 7.7 7.7 7.7 7.9 8.0 8.2Hungary 7.8 8.4 8.6 8.8 8.9 9.0 9.1 9.2 9.3 9.4 9.5Poland 5.9 5.9 6.0 6.0 6.0 6.1 6.3 6.4 6.5 6.6 6.6Russia 6.1 6.1 6.2 6.2 6.2 6.3 6.3 6.4 6.4 6.5 6.6Turkey 6.5 6.6 6.7 6.8 6.8 6.8 6.8 6.9 7.0 7.1 7.2

TOTAL 6.6 6.6 6.6 6.7 6.7 6.8 6.8 6.9 6.9 7.0 7.0

35P3B5-54



Region / Country 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

Middle East & Africa

Egypt 4.9 5.0 5.0 5.1 5.1 5.2 5.2 5.2 5.2 5.3 5.3Israel 8.7 8.8 8.8 9.0 9.1 9.1 9.2 9.3 9.4 9.5 9.6Saudi Arabia 4.3 4.3 4.4 4.4 4.4 4.5 4.5 4.5 4.6 4.6 4.7South Africa 8.7 8.2 9.4 8.2 8.1 8.2 8.2 8.2 8.2 8.2 8.2

TOTAL 6.1 6.1 6.1 6.2 6.2 6.2 6.2 6.3 6.2 6.3 6.3

WORLD TOTAL 10.2 10.2 10.3 10.3 10.4 10.6 10.7 10.9 11.0 11.2 11.4


Note1. Regional and World total are calculated using weighted average of countries in the region and are not the simple average.

The above figures represent Healthcare Expenditure as percentage of Gross Domestic Product.


36P3B5-54


Decision Support DatabaseTable Population 65 Plus (Mn)



Canada 4.1 4.2 4.2 4.3 4.4 4.5 4.6 4.7 4.9 5.0 5.2 2.66United States 35.6 35.9 36.3 36.7 37.2 37.9 38.7 39.5 40.2 41.1 42.6 2.14

TOTAL 39.7 40.1 40.5 41.0 41.6 42.4 43.3 44.2 45.1 46.1 47.7 2.19

Latin America


TOTAL 22.9 23.7 24.5 25.3 26.1 27.0 27.9 28.8 29.8 30.8 31.9 3.40

Asia - Pacific


TOTAL 193.8 199.2 204.3 209.6 215.4 221.4 227.1 233.2 239.4 246.0 254.0 2.79

37P3B5-54




(2005 - 2012)

Western Europe


TOTAL 65.4 66.4 67.4 68.4 69.3 70.0 70.8 71.7 72.4 73.3 74.6 1.24

Eastern Europe

Czech Republic 1.4 1.4 1.4 1.5 1.5 1.5 1.5 1.6 1.6 1.7 1.7 2.64Hungary 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.6 1.6 1.6 1.6 0.86Poland 4.9 5.0 5.0 5.1 5.1 5.1 5.2 5.2 5.2 5.3 5.4 0.83Russia 18.8 19.3 19.8 20.3 20.6 20.8 20.4 19.8 19.2 18.8 18.9 (1.38)Turkey 4.2 4.4 4.5 4.7 4.8 4.9 5.1 5.2 5.3 5.5 5.6 2.54

TOTAL 30.8 31.6 32.3 33.0 33.5 33.9 33.7 33.3 32.9 32.8 33.2 (0.14)

38P3B5-54






TOTAL 6.4 6.6 6.7 6.9 7.1 7.4 7.6 7.8 8.0 8.3 8.6 3.09

WORLD TOTAL 358.9 367.4 375.7 384.3 393.1 402.0 410.3 418.9 427.6 437.4 450.1 2.28


The above figures represent total midyear population aged 65 years and above


39

About Frost & Sullivan

40P3B5-54

Who is Frost & Sullivan

The Growth Partnership Company

• Founded in 1961, Frost & Sullivan has over 45 years of assisting clients with their decision-making

and growth issues.

• Over 1,700 Growth Consultants and Industry Analysts across 32 global locations

• Over 10,000 clients worldwide - emerging companies, the global 1000 and the investment community

• Developers of the Growth Excellence Matrix – industry leading growth positioning tool for corporate

executives

• Developers of TEAM Methodology, proprietary process to ensure that clients receive a 360o

perspective of technology, markets and growth opportunities

• Three core services: Growth Partnership Services, Growth Consulting and Career Best

Practices

41P3B5-54

What Makes Us Unique

Exclusively Focused on Growth

Global thought leader exclusively focused on addressing client growth strategies and plans – Team actively engaged in researching and developing of growth models that enable clients to achieve aggressive growth objectives.

Industry Breadth

Cover the broad spectrum of industries and technologies to provide clients with the ability to look outside the box and discover new and innovative ideas.

Global Perspective

32 global offices ensure that clients receive a global coverage/perspective based on regional expertise.

360o Perspective

Proprietary TEAM Methodology integrates all 6 critical research methodologies to significantly enhance the accuracy of decision making and lower the risk of implementing growth strategies.

Growth Monitoring

Continuously monitor changing technology, markets and economics and proactively address clients growth initiatives and position.

Trusted Partner

Working closely with client Growth Teams – helping them generate new growth initiatives and leverage all of Frost & Sullivan assets to accelerate their growth.

42P3B5-54

TEAM Methodology

Frost & Sullivan’s proprietary TEAM methodology, ensures that clients have complete “360 Degree

Perspective” from which to drive decision-making. Technical, Econometric, Application, and Market

information ensures that clients have a comprehensive view of industries, markets and technology.

Technical Real-time intelligence on technology, including emerging technologies, new

R&D breakthroughs, technology forecasting, impact analysis, groundbreaking

research, and licensing opportunities.

Econometric In-depth qualitative and quantitative research focused on timely and critical

global, regional, and country specific trends, including the political,

demographic, and socioeconomic landscapes.

Application Insightful strategies, networking opportunities, and best practices that can be

applied for enhanced market growth; interactions between the client, peers, and

Frost & Sullivan representatives that result in added value and effectiveness.

Market Global and regional market analysis, including drivers and restraints, market

trends, regulatory changes, competitive insights, growth forecasts, industry

challenges, strategic recommendations, and end-user perspectives.

43P3B5-54

Global Perspective

• 1,700 staff across every major market worldwide

• Over 10,000 clients worldwide from emerging to global 1000 companies

Asia Pacific: Korea Healthcare Outlook 2010

Health & Medicine

Transcript of Asia Pacific: Korea Healthcare Outlook 2010